Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Antares Pharma, a provider of self injection drug delivery technology services, has received $0.5m sales-based milestone from Teva for achieving an undisclosed sales volume of Tev-Tropin.
Subscribe to our email newsletter
Antares’ delivery device, branded as Tjet is used to deliver Tev-Tropin brand human growth hormone (hGH) to children who have growth failure due to inadequate secretion of normal endogenous growth hormone.
Paul Wotton, president and CEO of Antares Pharma, said: “We are pleased to receive this milestone payment from Teva and believe that our Tjet injector system allows for a more user-friendly method of administration of Teva’s Tev-Tropin product, providing patients with a convenient means of injecting hGH on a daily basis.
“More significantly we believe all of Antares’ proprietary injectable platforms, which also include auto-injector and pen technologies, can improve patients’ lives and create meaningful value for its pharmaceutical partners.”